Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject gives voluntary written informed consent to participate in the study.~* Subject has been diagnosed with systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria.~* Males and females age greater than 18 years at time of Screening.~* Presence of active digital ulcer OR history of digital ulcer occurring within past 6 months at time of Screening and poorly controlled Raynaud's phenomenon (as documented by patient report of 6-10 episodes per week).~* Females of childbearing potential must be willing to use two forms of medically acceptable contraception (at least one barrier method) and have a negative pregnancy test at Screening, confirmed at Baseline if separate visits. Women who are surgically sterile or have been post-menopausal for at least 2 years are not considered to be of child-bearing potential.~* Subject agrees to abstain from consuming grapefruit containing food or beverages for 3 days prior to Baseline and until discharge from the study.~* Subject is able to communicate effectively with study personnel and be considered reliable, willing and cooperative in terms of compliance with the protocol requirements.~Exclusion Criteria:~* Has diagnosis of pulmonary arterial hypertension and receiving approved or investigational therapies for PAH, including endothelin receptor antagonists, phosphodiesterase inhibitors, or prostacyclin analogues.~* Body weight less than 40 kg at time of Screening, confirmed at Baseline.~* The subject has a history of postural hypotension, unexplained syncope, a blood pressure that is less than 85 mmHg systolic or 50 mmHg diastolic at Screening or Baseline.~* Hemoglobin concentration less than 75% of the lower limit of the normal range at time of Screening.~* AST and/or ALT concentrations greater than 3 times upper limit of normal (ULN) at time of Screening.~* Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.~* Intractable diarrhea, severe malabsorption, defined as greater than 15% unintentional loss of body weight in the last 6 months prior to Screening, or any severe organ failure (e.g., lung, kidney) or any life-threatening condition.~* Pregnancy or breast-feeding.~* Overlap with another connective tissue disease that could affect rest pain and hand function (e.g. diabetes mellitus, rheumatoid arthritis).~* Sympathectomy of the upper limb performed within 12 months of Baseline.~* Receipt of parenteral prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analog) within the previous 3 months for conditions including PAH, rest pain and / or digital ulcers.~* Treatment with gemfibrozil, glitazones, or cyclophosphamide within 1 week prior to Baseline.~* Treatment with rifampin within 4 weeks prior to Baseline.~* Local injection of botulinum toxin in an affected finger within 1 month prior to Baseline.~* Received systemic antibiotics to treat infection of digital ulcers within 2 weeks prior to Baseline.~* Treatment with phosphodiesterase inhibitors such as sildenafil, except for intermittent treatment of male erectile dysfunction.~* Received an investigational product within 1 month preceding Screening.~* Known hypersensitivity to oral treprostinil or any of the excipients.~* Cigarette smoking at any level within the past 6 months prior to Screening.~* Any condition that could prevent compliance with the protocol or adherence to therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treprostinil diethanolamine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).